Medical Device Tax Technical Hot Topics webcast: Successfully addressing the operational and systems implementation requirements of the Federal Medical Device Excise Tax (MDET)
Please join PwC for a complimentary Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast: Successfully addressing the operational and systems requirements of the Federal Medical Device Excise Tax on Thursday, 23 August, 2012 from 11:00 AM - 12:00 PM (US EST).
The webcast will be hosted by Michael Swanick, PwC Global Pharmaceutical and Life Sciences Tax Leader. The session will be led by Advisory Services principal Carlos Moreira, managing director John Moran and Tax director Fred Gordon.
Effective January 1, 2013, manufacturers and importers of most medical devices will be subject to a 2.3% federal excise tax on sales of products made in the US. By some estimates the cost of this tax will be as much as $100M-$200M per year for larger organizations. To comply with the requirements, a fully functional automated compliance system must be designed, built, tested and deployed by January 2013. During the webcast, PwC tax and consulting professionals will be presenting an update on the key considerations involved in developing and implementing the operational and systems requirements to meet the filing deadline. The session will include case study examples to highlight how companies are meeting the data and operational challenges of building an effective system to support the tax reporting provisions.
Webcast Registration and Login
To enter the webcast, please log on to the following URL 15 minutes prior to the scheduled start time to make sure you can access the webcast in advance.
Please note that CPE credit can only be given to individuals who remain logged into the live webcast and respond to the polling questions provided during the webcast. If you are viewing this webcast in a group, everyone in the group can receive CPE credit.
The law which was originally enacted as the Prescription Drug User Fee Act (PDUFA) and is re-authorized every five years, renews a commitment to applicant funding of FDA drug and device reviews, while requiring transparency, speed, and other process improvements. Funding for the agency from 2013 through 2017 is expected to substantially increase, and for the first time, generics and biosimilars are now subject to user fees; a significant change for a market that is shifting increasingly to the usage of generic medications.
The legislation revamps the medical device approval process and imposes stricter oversight of global drug and device supply chains. Also antibiotics and rare disease drug incentives are increased and drug shortages gain additional attention and resources. Click here to download the full report.
17th Annual Medicaid Drug Rebate Programs Summit
Septemeber 10-12, 2012, Chicago, IL
The MDRP Summit attracts the most industry, state and federal government professionals impacted by the MDRP program than any other event, so that you get the most current regulatory updates and industry practices to navigate the regulatory hurdles and optimize your budget. Hear from Finance heads of the major pharmaceutical manufacturers in the inaugural Life Science Leadership Forum for a top to bottom understanding of where your office fits into your company's macro level finance strategy and find out how companies are planning to implement the provisions in the AMP rule in the AMP Proposed Rule Symposium so you don't find yourself behind the curve. PwC is a sponsor of this conference. Click here for more information.